Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are ...

A new meta-analysis of six randomized controlled trials shows CagriSema significantly lowers HbA1c, body weight, and blood ...

Joint recommendation cites Corcept’s CATALYST study on the prevalence and treatment of hypercortisolism in patients whose blood sugar remains high despite use of multiple glucose-lowering medications ...

The European Association for the Study of Diabetes and the American Diabetes Association have updated their joint guidance on T2D management.

More than 29 million adults in the United States are diagnosed with type 2 diabetes, and insulin therapy is estimated to be needed in up to 15% of cases. Insulin should be considered first-line ...

The majority of patients with type 2 diabetes (T2D) have less than ideal metabolic control despite our greater understanding of the underlying pathophysiologic mechanisms of hyperglycemia and the ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) today authorised Onswik (insulin efsitora alfa) for the ...

Onswik is designed to reduce injections by over 300 per year versus once-daily basal insulin 1,2 With Onswik, Lilly's type 2 diabetes portfolio expands to include a once-weekly basal insulin, ...

Track late-stage GLP-1 innovation, once-weekly insulin, RNAi and gene therapies, plus licensing, partnerships and global clinical trial activity.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Type 2 ...

This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice. Conclusions: ...